共 16 条
[1]
Addington D.E., Jones B., Bloom D., Chouinard G., Remington G., Albright P., Reduction of hospital days in chronic schizophrenic patients treated with risperidone: Retrospective study, Clin Ther, 15, pp. 917-926, (1993)
[2]
Borison R.L., Pathiraja A.P., Diamorid B.I., Meibach R.C., Risperidone: Clinical safety and efficacy in schizophrenia, Psychopharmacol Bull, 28, pp. 213-218, (1992)
[3]
Chouinard G., Jones B., Remington G., Bloom D., Addington D., MacEwan G.W., Labelle A., Beauclair L., Amott W., A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients, J Clin Psychopharmacol, 13, pp. 20-25, (1993)
[4]
Claus A., Bollen J., De Cuyper H., Eneman M., Malfroid M., Peuskens J., Heylen S., Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: A multicentre double-blind comparative study, Acta Psychiatr Scand, 85, pp. 295-305, (1992)
[5]
Conners C.K., Conners’ Rating Scales Manual, Toronto, Multi-Health Systems, Inc., (1989)
[6]
Cozza S.J., Edison D.L., Risperidone in adolescents [Letter], J Am Acad Child Adolesc Psychiatry, 33, (1994)
[7]
Dwight M.M., Keck P.E., Stanton S.P., Strakowski S.M., McEIroy S.L., Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder, Lancet, 344, pp. 554-555, (1994)
[8]
Goodnick P.J., Risperidone treatment of refractory acute mania, J Clin Psychiatry, (1995)
[9]
Marder S.R., Risperidone: Clinical development: North American results, Clin Neuropharmacol, 15, 1, pp. 92A-93A, (1992)
[10]
Marder S.R., Meibach R.C., Risperidone in the treatment of schizophrenia, Am J Psychiatry, 151, pp. 825-835, (1994)